Suh Hong Seung Net Worth

Suh Hong Seung biography

Dr. Suh Hong Seung Ph.D. serves as Independent Director of the Company. Dr. Hong has served as a senior consultant of Celltrion Healthcare, a biopharmaceutical company, since February 2020, as well as Vice Chairman for Novelgen, a biopharmaceutical company, since April 2020, in South Korea. Dr. Hong has served as a consultant to a number of biopharmaceutical companies since March 2019. From April 2002 to January 2019, he served in various capacities at Celltrion Inc., a biopharmaceutical company, including as President of Celltrion Healthcare Japan and Senior Advisor from January 2016 to January 2019; as President and Chief Executive Officer of Celltrion Healthcare Co., Ltd. from November 2014 to December 2015; and as President of Research and Development from April 2002 to November 2014. Dr. Hong received a B.S. in Agricultural Chemistry, a M.S. in Industrial Enzymology, and a Ph.D. in Enzymology and Fermentation from Seoul National University. Dr. Hong also participated in post-doctoral studies at the University of Wisconsin-Madison. Hong is qualified to serve on our board of directors due to his executive leadership experience in the life sciences industry.

What is the salary of Suh Seung?

As the Independent Director of Ocular Therapeutix Inc, the total compensation of Suh Seung at Ocular Therapeutix Inc is $124,016. There are 10 executives at Ocular Therapeutix Inc getting paid more, with Antony Mattessich having the highest compensation of $2,126,150.

How old is Suh Seung?

Suh Seung is 62, he's been the Independent Director of Ocular Therapeutix Inc since 2019. There are 3 older and 13 younger executives at Ocular Therapeutix Inc. The oldest executive at Ocular Therapeutix Inc is Richard Lindstrom, 72, who is the Independent Director.

What's Suh Seung's mailing address?

Seung's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.

Insiders trading at Ocular Therapeutix Inc

Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer, and Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.

What does Ocular Therapeutix Inc do?

ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib

Ocular Therapeutix Inc executives and stock owners

Ocular Therapeutix Inc executives and other stock owners filed with the SEC include:

• Antony Mattessich,
  President, Chief Executive Officer, Director
• Patricia Kitchen,
  Chief Operations Officer
• Antony Mattessich,
  Pres, CEO & Director
• Michael Goldstein,
  Chief Medical Officer
• Donald Notman,
  Chief Financial Officer
• Dr. Michael H. Goldstein M.M., M.D., M.B.A.,
  Pres of Ophthalmology & Chief Medical Officer
• Patricia Kitchen,
  Chief Operating Officer
• Philip C. Strassburger,
  Gen. Counsel
• Leslie Williams,
  Independent Director
• Charles Warden,
  Independent Chairman of the Board
• Suh Hong Seung,
  Independent Director
• Bruce Peacock,
  Independent Director
• Richard Lindstrom,
  Independent Director
• Jeffrey Heier,
  Independent Director
• Christopher Brinzey,
  Managing Director
• Christopher White,
  Senior Vice President, Head of Business and Corporate Development
• Dr. Rabia Gurses Ozden,
  Sr. VP of Clinical Devel.
• Scott Corning,
  Sr. VP of Commercial
• Tracy Smith,
  VP of HR
• Christopher G. White,
  Chief Bus. Officer
• William H. Ransone II,
  VP of Global Sales & Marketing
• Dr. Peter K. Jarrett Ph.D.,
  Chief Scientific Officer
• Donald Notman Jr.,
  Chief Financial Officer
• Jaswinder Chadha,
  Director
• Jonathan H. Talamo,
  Chief Medical Officer
• Charles Andrew Hurley,
  Chief Commercial Officer
• James M Garvey,
  Director
• James Fortune,
  Chief Operating Officer
• Amarpreet Sawhney,
  President and CEO
• William J Oshea,
  Director
• Eric Ankerud,
  See Remarks
• W Bradford Smith,
  CFO and Treasurer
• Pravin Dugel,
  See Remarks
• Rabia Gurses Ozden,
  Chief Medical Officer
• Daniel M Bollag,
  Sr. VP Reg. Affairs & Quality
• Kevin F. Hanley,
  Sr. VP Technical Operations
• Management Inc. Opaleye,
  
• Venture Management Co. V, L...,
  
• Ii, L.P.Ascension Health Ve...,
  
• Iv, Llcsv Life Sciences Fun...,
  
• Venture Capital Iii, L.P.Ve...,
  
• Iv, Llcsv Life Sciences Fun...,
  
• Road Llc Summer,
  
• Merilee Raines,
  Director
• Philip C. Strassburger,
  General Counsel
• Sanjay Nayak,
  Chief Strategy Officer
• Nadia Waheed,
  Chief Medical Officer